Multivariate analysis of factors associated with GVHD, relapse, and TRM in patients undergoing reduced-intensity or nonmyeloablative unrelated donor PBSC transplantation
| Variable . | n . | RR (95% CI) . | P . |
|---|---|---|---|
| Grades II-IV acute GVHD | |||
| GVHD prophylaxis | |||
| CsA-based | 215 | 1.00 | |
| FK506-based | 99 | 0.62 (0.40-0.98) | .040 |
| Year of transplantation | .028 | ||
| 1999-2000 | 43 | 1.00 | |
| 2001 | 53 | 0.74 (0.42-1.31) | .307 |
| 2002 | 93 | 0.56 (0.33-0.95) | .033 |
| 2003 | 125 | 0.47 (0.28-0.79) | .004 |
| Grades III-IV acute GVHD | |||
| GVHD prophylaxis | |||
| CsA-based | 215 | 1.00 | |
| FK506-based | 99 | 0.52 (0.28-0.95) | .033 |
| Year of transplantation | .016 | ||
| 1999-2000 | 43 | 1.00 | |
| 2001 | 53 | 1.06 (0.51-2.18) | .877 |
| 2002 | 93 | 0.56 (0.27-1.15) | .114 |
| 2003 | 125 | 0.41 (0.20-0.85) | .016 |
| Conditioning intensity | |||
| Reduced intensity | 159 | 1.00 | |
| Nonmyeloablative | 155 | 0.37 (0.22-0.64) | < .001 |
| Relapse | |||
| Disease risk | .005 | ||
| Early | 114 | 1.00 | |
| Intermediate | 107 | 1.15 (0.71-1.84) | .572 |
| Advanced | 95 | 2.00 (1.27-3.14) | .003 |
| Transplant-related mortality | |||
| CD34+ cells dose, × 106/kg) | .039 | ||
| No more than 4.5 | 79 | 1.00 | |
| More than 4.5 | 154 | 0.56 (0.36-0.88) | .013 |
| Missing | 83 | 0.63 (0.38-1.04) | .073 |
| Disease risk | .029 | ||
| Early | 114 | 1.00 | |
| Intermediate | 107 | 1.38 (0.87-2.18) | .175 |
| Advanced | 95 | 1.91 (1.18-3.09) | .008 |
| Variable . | n . | RR (95% CI) . | P . |
|---|---|---|---|
| Grades II-IV acute GVHD | |||
| GVHD prophylaxis | |||
| CsA-based | 215 | 1.00 | |
| FK506-based | 99 | 0.62 (0.40-0.98) | .040 |
| Year of transplantation | .028 | ||
| 1999-2000 | 43 | 1.00 | |
| 2001 | 53 | 0.74 (0.42-1.31) | .307 |
| 2002 | 93 | 0.56 (0.33-0.95) | .033 |
| 2003 | 125 | 0.47 (0.28-0.79) | .004 |
| Grades III-IV acute GVHD | |||
| GVHD prophylaxis | |||
| CsA-based | 215 | 1.00 | |
| FK506-based | 99 | 0.52 (0.28-0.95) | .033 |
| Year of transplantation | .016 | ||
| 1999-2000 | 43 | 1.00 | |
| 2001 | 53 | 1.06 (0.51-2.18) | .877 |
| 2002 | 93 | 0.56 (0.27-1.15) | .114 |
| 2003 | 125 | 0.41 (0.20-0.85) | .016 |
| Conditioning intensity | |||
| Reduced intensity | 159 | 1.00 | |
| Nonmyeloablative | 155 | 0.37 (0.22-0.64) | < .001 |
| Relapse | |||
| Disease risk | .005 | ||
| Early | 114 | 1.00 | |
| Intermediate | 107 | 1.15 (0.71-1.84) | .572 |
| Advanced | 95 | 2.00 (1.27-3.14) | .003 |
| Transplant-related mortality | |||
| CD34+ cells dose, × 106/kg) | .039 | ||
| No more than 4.5 | 79 | 1.00 | |
| More than 4.5 | 154 | 0.56 (0.36-0.88) | .013 |
| Missing | 83 | 0.63 (0.38-1.04) | .073 |
| Disease risk | .029 | ||
| Early | 114 | 1.00 | |
| Intermediate | 107 | 1.38 (0.87-2.18) | .175 |
| Advanced | 95 | 1.91 (1.18-3.09) | .008 |